The potential economic impact of restricted access to angiotensin-receptor blockers

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 3, 2011, Pages

  Guertin, Jason R ^a   Jackevicius, Cynthia A ^b,c   Cox, Jafna L ^d   Humphries, Karin ^e   Pilote, Louise ^f   So, Derek Y ^g   Tu, Jack V ^c,h   Wijeysundera, Harindra ^h   Rinfret, Stéphane ⁱ  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^h SUNNYBROOK RESEARCH INSTITUTE   (Canada)

ⁱ LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; CAPTOPRIL; CILAZAPRIL; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ABSENCE OF SIDE EFFECTS; ARTICLE; CARDIOVASCULAR DISEASE; COST CONTROL; COST MINIMIZATION ANALYSIS; COUGHING; DECISION TREE; DRUG COST; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; ECONOMIC ASPECT; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; MONTE CARLO METHOD; PHARMACY;

EID: 79951970041     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.100787     Document Type: Article

References (28)

1. Jackevicius CA, Cox JL, Carreon D, et al. Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ 2009;181:E19-E28.
2. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
3. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice? Lancet 2004;364:1684-9. (Pubitemid 39458144)
4. Kaplan NM. Beta-blockers in hypertension: adding insult to injury. J Am Coll Cardiol 2008;52:1490-1.
5. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129(Suppl):169S- 73S.
6. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29. (Pubitemid 351664943)
7. Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004;141:693-704. (Pubitemid 39434842)
8. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358: 1547-59. (Pubitemid 351522739)
9. Jackevicius CA, Tu JV, Ross JS, et al. Use of ezetimibe in the United States and Canada. N Engl J Med 2008;358:1819-28. (Pubitemid 351581194)
10. Pilote L, Abrahamowicz M, Rodrigues E, et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: A class effect? Ann Intern Med 2004;141:102-12.
11. Manuel des médecins omnipraticiens. Quebec City (QC): Régis de l'assurance maladie du Québec; 2005. Available: www.ramq.gouv.qc.ca/ fr/professionnels/manuels/100/000-complet-acte-omni.pdf (ac cessed 2010 Aug. 16).
12. Schedule of benefits for physician services under the Health Insurance Act. Toronto (ON): Ministry of Health and Long-Term Care; 2010. Available: www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv-mn. html (accessed 2010 Aug. 16).
13. Alberta Health and Wellness schedule of medical benefits. Alberta Health Care Insurance Plan: medical price list as of 01 October 2010. Edmonton (AB): Government of Alberta; 2010. Available: www.health.alberta.ca/documents/SOMB- medical-price-list.pdf (accessed 2010 Aug. 16).
14. Saskatchewan Health payment schedule for insured services provided by a physician. In: Saskatchewan Health regional health services policy and procedure manual: payment schedule for Saskatchewan physicians. Regina (SK): Saskatchewan Health; 2008. Available: www.health.gov.sk.ca/physician-payment-schedule- october-2008 (accessed 2010 Aug. 16).
15. Manitoba physician's manual. Winnipeg (MB): Manitoba Health; 2010. Available: www.gov.mb.ca/health/documents/physmanual.pdf (accessed 2010 Aug. 16).
16. Physician's manual: medicare. Schedule of fees of the New Brunswick Medical Society, March 27, 2008. Fredericton (NB): New Brunswick Medical Society; 2008. Available: www.gnb.ca/0394/pdf-en/PhysiciansManual-e.pdf (accessed 2010 Aug. 16).
17. Physician's manual. Halifax (NS): Nova Scotia Medical Services Insurance; 2010. Available: www.gov.ns.ca/health/reports/pubs/MSI-Physicians-Manual-2010. pdf (accessed 2010 Aug. 16).
18. Payment schedule: medical care plan. St. John's (NL): Department of Health and Community Services; 2009. Available: www.health.gov.nl.ca/health/mcp/ providers/full-mcp-payment-schedule.pdf (accessed 2010 Aug. 16).
19. Schneeweiss S, Dormuth C, Grootendorst P, et al. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care 2004;42:653-60.
20. Entente entre l'Association québécoise des pharmaciens propriétaires et le Ministre de la Santé et Services sociaux. Québec (QC): Régie de l'assurance maladie du Québec; 2009.
21. Patent Register. Available: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/ patregbrev/index-eng.php (accessed 2010 Sept. 14).
22. Sheehy O, LeLorier J, Rinfret S. Restrictive access to clopidogrel and mortality following coronary stent implantation. CMAJ 2008;178:413-20. (Pubitemid 351303283)
23. Jackevicius CA, Tu JV, Demers V, et al. Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med 2008;359:1802-10.
24. Wettermark B, Godman B, Neovius M, et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 2010;94:221-9.
25. Stankus V, Hemmelgarn B, Campbell NR, et al. Reducing costs and improving hypertension management. Can J Clin Pharmacol 2009;16:e151-5.
26. Romanow RJ. Building on values. The future of health care in Canada - final report. Ottawa (ON): Commission on the Future of Health Care in Canada; 2002. Available: http://publications.gc.ca/site/eng/237274/publication.html (accessed 2010 Dec. 17).
27. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007;298:61-9. (Pubitemid 47026771)
28. Cicardi M, Zingale LC, Bergamaschini L, et al. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004;164:910-3. (Pubitemid 38520634)